178 related articles for article (PubMed ID: 36646020)
21. Acute and chronic effects of cannabidiol on Δ⁹-tetrahydrocannabinol (Δ⁹-THC)-induced disruption in stop signal task performance.
Jacobs DS; Kohut SJ; Jiang S; Nikas SP; Makriyannis A; Bergman J
Exp Clin Psychopharmacol; 2016 Oct; 24(5):320-330. PubMed ID: 27690502
[TBL] [Abstract][Full Text] [Related]
22. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.
Bhattacharyya S; Morrison PD; Fusar-Poli P; Martin-Santos R; Borgwardt S; Winton-Brown T; Nosarti C; O' Carroll CM; Seal M; Allen P; Mehta MA; Stone JM; Tunstall N; Giampietro V; Kapur S; Murray RM; Zuardi AW; Crippa JA; Atakan Z; McGuire PK
Neuropsychopharmacology; 2010 Feb; 35(3):764-74. PubMed ID: 19924114
[TBL] [Abstract][Full Text] [Related]
23. Combination of Cannabinoids, Δ9- Tetrahydrocannabinol and Cannabidiol, Ameliorates Experimental Multiple Sclerosis by Suppressing Neuroinflammation Through Regulation of miRNA-Mediated Signaling Pathways.
Al-Ghezi ZZ; Miranda K; Nagarkatti M; Nagarkatti PS
Front Immunol; 2019; 10():1921. PubMed ID: 31497013
[TBL] [Abstract][Full Text] [Related]
24. Absence of interaction between delta9-tetrahydrocannabinol (delta-THC) and cannabidiol (CBD) in aggression, muscle control and body temperature experiments in mice.
Ham MT; De Jong Y
Psychopharmacologia; 1975; 41(2):169-74. PubMed ID: 1171491
[TBL] [Abstract][Full Text] [Related]
25. A Critical Review of the Role of the Cannabinoid Compounds Δ
Jones É; Vlachou S
Molecules; 2020 Oct; 25(21):. PubMed ID: 33113776
[TBL] [Abstract][Full Text] [Related]
26. Effects of oral Δ9-tetrahydrocannabinol and cannabidiol combinations on a sustained attention task in rats.
Moore CF; Davis CM; Sempio C; Klawitter J; Christians U; Weerts EM
Exp Clin Psychopharmacol; 2023 Oct; 31(5):881-887. PubMed ID: 36634015
[TBL] [Abstract][Full Text] [Related]
27. Effects of daily Δ
Withey SL; Kangas BD; Charles S; Gumbert AB; Eisold JE; George SR; Bergman J; Madras BK
Drug Alcohol Depend; 2021 Apr; 221():108629. PubMed ID: 33640678
[TBL] [Abstract][Full Text] [Related]
28. Contribution of the Adenosine 2A Receptor to Behavioral Effects of Tetrahydrocannabinol, Cannabidiol and PECS-101.
Stollenwerk TM; Pollock S; Hillard CJ
Molecules; 2021 Sep; 26(17):. PubMed ID: 34500787
[TBL] [Abstract][Full Text] [Related]
29. A crowdsourcing survey study on the subjective effects of delta-8-tetrahydrocannabinol relative to delta-9-tetrahydrocannabinol and cannabidiol.
Bergeria CL; Strickland JC; Spindle TR; Kalaba M; Satyavolu PU; Feldner M; Vandrey R; Bonn-Miller M; Peters EN; Weerts E
Exp Clin Psychopharmacol; 2023 Apr; 31(2):312-317. PubMed ID: 35467921
[TBL] [Abstract][Full Text] [Related]
30. Neural correlates of interactions between cannabidiol and Δ(9) -tetrahydrocannabinol in mice: implications for medical cannabis.
Todd SM; Arnold JC
Br J Pharmacol; 2016 Jan; 173(1):53-65. PubMed ID: 26377899
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic Use of Δ9-THC and Cannabidiol: Evaluation of a New Extraction Procedure for the Preparation of Cannabis-based Olive Oil.
Morini L; Porro G; Liso M; Groppi A
Curr Pharm Biotechnol; 2017; 18(10):828-833. PubMed ID: 29189144
[TBL] [Abstract][Full Text] [Related]
32. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.
Fusar-Poli P; Crippa JA; Bhattacharyya S; Borgwardt SJ; Allen P; Martin-Santos R; Seal M; Surguladze SA; O'Carrol C; Atakan Z; Zuardi AW; McGuire PK
Arch Gen Psychiatry; 2009 Jan; 66(1):95-105. PubMed ID: 19124693
[TBL] [Abstract][Full Text] [Related]
33. Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Relevant to Electronic Cigarette Liquids.
Hindelang P; Scharinger A; Richling E; Walch SG; Lachenmeier DW
Front Biosci (Landmark Ed); 2022 Jul; 27(8):228. PubMed ID: 36042166
[TBL] [Abstract][Full Text] [Related]
34. Cannabidiol and Delta-9-Tetrahydrocannabinol Interactions in Male and Female Rats With Persistent Inflammatory Pain.
Britch SC; Craft RM
J Pain; 2023 Jan; 24(1):98-111. PubMed ID: 36122809
[TBL] [Abstract][Full Text] [Related]
35. Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study.
Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC
J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):561-570. PubMed ID: 34412109
[TBL] [Abstract][Full Text] [Related]
36. Oral efficacy of Δ(9)-tetrahydrocannabinol and cannabidiol in a mouse neuropathic pain model.
Mitchell VA; Harley J; Casey SL; Vaughan AC; Winters BL; Vaughan CW
Neuropharmacology; 2021 May; 189():108529. PubMed ID: 33741405
[TBL] [Abstract][Full Text] [Related]
37. Acute effects of Δ
Greenwood LM; Broyd SJ; van Hell HH; Todd J; Jones A; Murray RM; Croft RJ; Michie PT; Solowij N
Psychopharmacology (Berl); 2022 May; 239(5):1409-1424. PubMed ID: 34719731
[TBL] [Abstract][Full Text] [Related]
38. Δ9-Tetrahydrocannabinol alone and combined with cannabidiol mitigate fear memory through reconsolidation disruption.
Stern CA; Gazarini L; Vanvossen AC; Zuardi AW; Galve-Roperh I; Guimaraes FS; Takahashi RN; Bertoglio LJ
Eur Neuropsychopharmacol; 2015 Jun; 25(6):958-65. PubMed ID: 25799920
[TBL] [Abstract][Full Text] [Related]
39. The Effect of Orally Administered Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) on Obesity Parameters in Mice.
Eitan A; Gover O; Sulimani L; Meiri D; Schwartz B
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762099
[TBL] [Abstract][Full Text] [Related]
40. Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery.
Del Pozo A; Barker-Haliski M
Exp Neurol; 2023 Feb; 360():114288. PubMed ID: 36471511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
